TransCode Therapeutics, Inc. (RNAZ)Healthcare | Biotechnology | Boston, United States | NasdaqCM
8.80 USD
+0.10
(1.149%)
⇧
(April 17, 2026, 4 p.m.
EDT)
After hours: 8.97 +0.17 (1.932%) ⇧ (April 17, 2026, 7:04 p.m. EDT) Short-term: ★★★★★ | Long-term: ★☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 18, 2026, 10:09 p.m. EDT
RNAZ is a high-conviction near-term momentum play driven by recent positive glioblastoma data, leading $25M financing, and a major acquisition of Polynoma; however, it remains a dangerous long-term hold due to negative earnings, high cash burn, no dividend, and a negative forward P/E, making it a speculative vehicle for capital appreciation only. |
| Model | MAE |
|---|---|
| MSTL ✓ | 0.079515 |
| AutoETS | 0.094826 |
| AutoARIMA | 0.094826 |
| AutoTheta | 0.117095 |
Forecast horizon: 45 days | Selected: MSTL
| Forecast Reliability | |
|---|---|
| Score | 79% |
| H-stat | 0.09 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.111 |
| Excess Kurtosis | 0.35 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 8,069,318 |
| Forward P/E | -14.67 |
| Website | https://www.transcodetherapeutics.com |
| Attribute | Value |
|---|---|
| 52 Week Change | 0.047619104 |
| Address1 | 6 Liberty Square |
| Address2 | Suite 2382 |
| All Time High | 5,174,400.0 |
| All Time Low | 6.083 |
| Ask | 11.2 |
| Ask Size | 2 |
| Average Daily Volume10 Day | 7,130 |
| Average Daily Volume3 Month | 207,072 |
| Average Volume | 207,072 |
| Average Volume10Days | 7,130 |
| Bid | 6.17 |
| Bid Size | 2 |
| Book Value | 1.71 |
| City | Boston |
| Compensation As Of Epoch Date | 1,735,603,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 8.8 |
| Current Ratio | 6.291 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 9.0 |
| Day Low | 8.61 |
| Display Name | TransCode Therapeutics |
| Ebitda | -27,903,624 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.723 |
| Enterprise Value | 131,800,336 |
| Eps Forward | -0.6 |
| Eps Trailing Twelve Months | -52.59 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 9.3084 |
| Fifty Day Average Change | -0.50839996 |
| Fifty Day Average Change Percent | -0.05461733 |
| Fifty Two Week Change Percent | 4.7619104 |
| Fifty Two Week High | 22.036 |
| Fifty Two Week High Change | -13.235999 |
| Fifty Two Week High Change Percent | -0.60065347 |
| Fifty Two Week Low | 6.083 |
| Fifty Two Week Low Change | 2.717 |
| Fifty Two Week Low Change Percent | 0.4466546 |
| Fifty Two Week Range | 6.083 - 22.036 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,625,751,000,000 |
| Float Shares | 832,424 |
| Forward Eps | -0.6 |
| Forward P E | -14.666666 |
| Free Cashflow | -19,511,556 |
| Full Exchange Name | NasdaqCM |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.0922 |
| Held Percent Institutions | 0.056739997 |
| Implied Shares Outstanding | 916,968 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-07-09 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,747,267,200 |
| Last Split Factor | 1:28 |
| Long Business Summary | TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts. |
| Long Name | TransCode Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 8,069,318 |
| Market State | CLOSED |
| Max Age | 86,400 |
| Message Board Id | finmb_546709785 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -33,050,864 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 8,069,318 |
| Open | 9.0 |
| Operating Cashflow | -19,516,228 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 857 837 3099 |
| Post Market Change | 0.17000008 |
| Post Market Change Percent | 1.931819 |
| Post Market Price | 8.97 |
| Post Market Time | 1,776,467,065 |
| Previous Close | 8.7 |
| Price Hint | 2 |
| Price To Book | 5.1461987 |
| Profit Margins | 0.0 |
| Quick Ratio | 5.371 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | none |
| Region | US |
| Regular Market Change | 0.1 |
| Regular Market Change Percent | 1.14943 |
| Regular Market Day High | 9.0 |
| Regular Market Day Low | 8.61 |
| Regular Market Day Range | 8.61 - 9.0 |
| Regular Market Open | 9.0 |
| Regular Market Previous Close | 8.7 |
| Regular Market Price | 8.8 |
| Regular Market Time | 1,776,456,000 |
| Regular Market Volume | 4,290 |
| Return On Assets | -0.20611 |
| Return On Equity | -0.46258 |
| Sand P52 Week Change | 0.38150132 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 916,968 |
| Shares Percent Shares Out | 0.0545 |
| Shares Short | 49,976 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 77,552 |
| Short Name | TransCode Therapeutics, Inc. |
| Short Percent Of Float | 0.0545 |
| Short Ratio | 4.87 |
| Source Interval | 15 |
| State | MA |
| Symbol | RNAZ |
| Total Cash | 17,813,520 |
| Total Cash Per Share | 19.427 |
| Total Debt | 0 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -52.59 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 9.937285 |
| Two Hundred Day Average Change | -1.1372852 |
| Two Hundred Day Average Change Percent | -0.11444627 |
| Type Disp | Equity |
| Volume | 4,290 |
| Website | https://www.transcodetherapeutics.com |
| Zip | 2,109 |